Avant Technologies, Inc. is an an emerging technology company developing solutions in healthcare using artificial intelligence technology and bio technologies. Avant and its partner, Ainnova Tech, Inc., formed Ai-Nova Acquisition Corp. (AAC), a joint venture company created to advance AI in healthcare and commercialize Ainnova's technology portfolio globally, including its Vision AI platform and its proprietary versatile retinal camera technology. Vision AI is a cutting-edge, AI-driven platform that can detect diabetic retinopathy and other retinal diseases, as well as diseases unrelated to the retina like cardiovascular disease, chronic kidney disease, prediabetes and type 2 diabetes, liver fibrosis, and lung abnormalities in CT scans and X-rays, including lung cancer, with high accuracy and speed using retinal scans. Ainnova's next-generation versatile retinal cameras are seamlessly integrated with Vision AI for precise retinal scans. Ainnova's Vision AI software, combined with its retinal cameras, will offer AAC SaaS + retinal camera commercialization opportunities with opticians and eye care centers worldwide. Avant and Ainnova are currently planning for FDA clinical studies for both the Vision AI platform and the retinal camera technology, which will culminate with an FDA 510(k) submission to obtain clearance from the FDA to market its technology in the U.S.
